Stephanie Davis, PA
Physician Assistant · Anderson, SCNPI 1033402151
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (42.0%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. 34 manufacturers reported payments, led by Lilly USA, LLC at 34.6% of the total. Reporting peaked in 2021 at $40,694 and has fallen 83.9% since, to $6,571 in 2025. Among physician assistant clinicians in SC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 943 payments — averaging $82.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$27K
- Janssen Scientific Affairs, LLC$11K
- Incyte Corporation$9K
- Novartis$6K
- UCB, Inc.$6K
- AbbVie$4K
- plus $15K from 28 others
What the payments were for
- Consulting fees$26,03333%
- Speaking & faculty fees$32,68342%
- Travel & lodging$2,5783%
- Food & beverage$15,48220%
- Education$9551%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 123 | $26,882 |
| Janssen Scientific Affairs, LLC | 15 | $10,809 |
| Incyte Corporation | 37 | $9,002 |
| Novartis | 50 | $5,779 |
| UCB, Inc. | 92 | $5,738 |
| AbbVie | 157 | $4,036 |
| Eli Lilly | 4 | $3,228 |
| Johnson & Johnson(2 entities) | 109 | $2,827 |
| Sanofi | 35 | $2,046 |
| Sun Pharmaceutical Industries Inc. | 48 | $1,682 |
| Genentech USA, Inc. | 1 | $900 |
| Regeneron Healthcare Solutions, Inc. | 36 | $829 |
| Galderma Laboratories, L.p. | 53 | $581 |
| Pfizer | 36 | $573 |
| Ortho Dermatologics, A Division Of Bausch Health US, LLC | 35 | $522 |
| LEO Pharma Inc. | 23 | $470 |
| Amgen | 24 | $460 |
| E.r. Squibb & Sons, L.L.C. | 18 | $449 |
| Arcutis Biotherapeutics, Inc. | 10 | $259 |
| Dermavant Sciences, Inc. | 15 | $212 |
| Organon | 5 | $103 |
| Boehringer Ingelheim | 2 | $42 |
| Sandoz | 2 | $40 |
| Paratek Pharmaceuticals, Inc. | 2 | $36 |
| Botanix SB Inc | 2 | $34 |
| Sanofi-aventis U.S. LLC | 1 | $29 |
| Tempus AI, Inc | 1 | $25 |
| Regeneron | 1 | $25 |
| Bausch Health US, LLC | 1 | $24 |
| Blueprint Medicines Corporation | 1 | $24 |
| Biofrontera Inc. | 1 | $19 |
| Stemline Therapeutics Inc. | 1 | $18 |
| VYNE Pharmaceuticals Inc. | 1 | $18 |
| Mayne Pharma Commercial LLC | 1 | $9 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$77,730 in reported general payments places this provider in the 95th percentile of 1,852 physician assistant providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Skyrizi PenRisankizumab-Rzaa | 33 | $671,790 |
| Dupixent PenDupilumab | 72 | $282,285 |
| Taltz AutoinjectorIxekizumab | 38 | $281,847 |
| Cosentyx Sensoready (2 Pens)Secukinumab | 34 | $248,776 |
| TremfyaGuselkumab | 16 | $221,018 |
| Humira(Cf) PenAdalimumab | 15 | $209,613 |
| Cosentyx Unoready PenSecukinumab | 16 | $113,470 |
| Dupixent SyringeDupilumab | 22 | $87,403 |
| Enbrel SureclickEtanercept | 12 | $82,359 |
| OtezlaApremilast | 16 | $66,075 |
| Clobetasol Propionate | 185 | $6,290 |
| Ketoconazole | 334 | $5,011 |
| Triamcinolone Acetonide | 317 | $3,082 |
| Metronidazole | 66 | $2,380 |
| Fluorouracil | 31 | $2,272 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonTremfya | $2,827 | $221,01816 claims |
| AmgenOtezla | $460 | $66,07516 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,852 physician assistant providers in South Carolina.
Other physician assistant in Anderson
- Sarah BrendleAnderson$19K
- Harley BeeseAnderson$14K
- Benjamin AddyWest Columbia$377K
- Michael OvercashCharleston$210K
- Allison LesterMt Pleasant$163K
- Nicole KeeterFort Mill$129K
- William YoungGreenville$117K
- Vicki RobertsWest Columbia$77K
- Eric ShoupColumbia$74K
- Lauren OlsonNorth Charleston$62K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.